All In Biotech

Drug Trial Radar · NCT01327846

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Last checked: Nov 19, 2026Latest source record: Jan 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 10,066 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

10,066

Actual

Start

Apr 11, 2011

Primary completion

Mar 28, 2017

Study completion Apr 14, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular events. The purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who participated in the pivotal phase. Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the carotid plaque burden measured by integrated vascular MRI in patients enrolled in the CACZ885M2301 study (CANTOS). Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether, in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared to placebo, on top of standard of care could increase insulin secretion and insulin sensitivity.

Conditions

  • Atherosclerosis

Interventions

  • CanakinumabDrug

  • PlaceboDrug

  • Standard of careDrug

    Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Analysis of Core Phase First CEC Confirmed Major Adverse Cardiovascular Events (MACE) and Its ComponentsTime frame: From randomization, to end of treatment plus 30 days, up to approximately 6 years
  2. Substudy 1 (Core Phase): Change From Baseline in Carotid Plaque Burden in the Bifurcation Region of the Index Carotid ArteryTime frame: 24 months
  3. Substudy 2 (Core Phase): Change From Baseline of the Insulin Secretion Rate (ISR) Relative to Glucose 0-30 Min Defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 Averaged Across the Year 3, 4, 5 VisitsTime frame: From randomization up to approximately 6 years

Locations

1,131 sites in 40 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Athens, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Fairhope, Alabama

  • Novartis Investigative Site

    Huntsville, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Mobile, Alabama

  • Novartis Investigative Site

    Anchorage, Alaska

  • Novartis Investigative Site

    Chandler, Arizona

  • Novartis Investigative Site

    Glendale, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Hot Springs, Arkansas

  • Novartis Investigative Site

    Jonesboro, Arkansas

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Carmichael, California

  • Novartis Investigative Site

    Escondido, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Huntington Beach, California

  • Novartis Investigative Site

    Lancaster, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Long Beach, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Gatos, California

  • Novartis Investigative Site

    Mission Viejo, California

  • Novartis Investigative Site

    Newport Beach, California

  • Novartis Investigative Site

    Northridge, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Orangevale, California

  • Novartis Investigative Site

    Palm Springs, California

  • Novartis Investigative Site

    Pasadena, California

  • Novartis Investigative Site

    Pomona, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Diego, California

Showing 40 of 1,131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.